|
Enzalutamide (E) re-challenge as second-line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with first-line enzalutamide + docetaxel (D): Preliminary results of a post-progression analysis of CHEIRON trial. |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Pfizer; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Medivation; Janssen |
Speakers' Bureau - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Novartis; Pfizer; Sanofi |
|
|
Travel, Accommodations, Expenses - Janssen; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Oncology; Ipsen; Janssen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sanofi |
Travel, Accommodations, Expenses - Pfizer |
Other Relationship - Astellas Oncology; Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen-Cilag; Sanofi |
Speakers' Bureau - Astellas Pharma; Janssen; Janssen; Pfizer; Sanofi |